Company intelligence / Profile preview

Symprove

Farnham, England, United Kingdom

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Symprove is a water-based, multi-strain live bacterial product clinically shown to deliver live bacteria to the gut, with independent studies supporting its capacity to reach the gut alive, survive passage through the stomach, and improve digestive symptoms. Surveys report that 94% of users feel a positive difference in 12 weeks or less, supported by randomized controlled trials at leading UK academic centers.[2][4][5][6]

Therapeutic areas: Gastroenterology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Symprove.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symprove.

Explore the full profile